Skip to main content

Counts of and Characterization of Mortality Capture Among Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
long-acting injectable antipsychotics
Health Outcome(s)
mortality
Description

In this report we obtained counts of prevalent long-acting injectable antipsychotic (LAIA) users and episodes in the Sentinel Distributed Database (SDD) and examined the feasibility of capturing evidence of death subsequent to LAIA exposures (i.e., treatment episodes that were censored due to death). This request was distributed to Sentinel Data Partners (DPs) on June 26,2019.

  • Report 1: This report contains data from eight DPs and the study period includes data from January 1, 2000 to March 31, 2018.
  • Report 2: This report contains data from eight DPs and the study period includes data from January 1, 2000 to March 31, 2018.
Deliverables (2)
Sentinel Modular Program Report: Counts of and Characterization of Mortality Capture Among Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis, Report 1 Sentinel Modular Program Report: Counts of and Characterization of Mortality Capture Among Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis, Report 2
Additional Details
FDA Center
CDER
Time Period
January 1, 2000 - March 31, 2018
Analysis Type
Descriptive
Population / Cohort
All individuals
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Long-Acting Injectable Antipsychotics & Mortality